Professor, Medicine, University of Colorado School of Medicine
Cardiology
Dr. Michael Bristow, MD
|
|
Give Review
Doctor Michael Bristow, MD is an expert in the field of Cardiology. He went to medical school at University of Illinois College of Medicine. He received awards:"Elected Member" and "Fellow (FACC)". Michael Bristow is a published doctor as well. He has 81 publications published. The latest was: Sex-related differences in age-associated downregulation of human ventricular myocardial 1-adrenergic receptors. Michael Bristow accepts all Medicare patients.
Publications
- Therapeutic Molecular Phenotype of β-blocker Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy.
- Race, Common Genetic Variation, and Therapeutic Response Disparities in Heart Failure.
- H2 receptor antagonists and right ventricular morphology: The MESA Right Ventricle Study.
- Polymorphic Variation in the G-Protein Beta-3 Subunit Gene and Response to BiDil in the A-HeFT: Basis for an African-American Pharmacogenetic Advantage to Nitric Oxide...
- New Onset Atrial Fibrillation Predicts Heart Failure Progression.
- Delta-6-desaturase Links PUFA Metabolism with Phospholipid Remodeling and Disease Progression in Heart Failure.
- Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta1389 Arg/Gly Adrenergic Receptor Polymorphism.
- Biomarker-guided therapies in heart failure: a forum for unified strategies.
- Treatment of the heart failure patient with atrial fibrillation: a major unmet need.
- Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
- Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
- A Personalized BEST: Characterization of Latent Clinical Classes of Nonischemic Heart Failure That Predict Outcomes and Response to Bucindolol.
- Treatment of Chronic Heart Failure With ?-Adrenergic Receptor Antagonists: A Convergence of Receptor Pharmacology and Clinical Cardiology.
- Aptamer therapy for heart failure?
- Pharmacogenetics in heart failure trials.
- Temporal Analysis of mRNA and miRNA Expression in Transgenic Mice Over Expressing Arg- and Gly389 Polymorphic Variants of the {beta}1-Adrenergic Receptor.
- Influence of global region on outcomes in heart failure Beta-blocker trials.
- Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study.
- Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3.
- Regional Left Ventricular Systolic Function and the Right Ventricle: The MESA-Right Ventricle Study.
- Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure.
- Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart.
- An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
- Targeting heart failure therapeutics: a historical perspective.
- Phosphodiesterase inhibition in heart failure.
- Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart.
- Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy.
- Influence of left ventricular lead location on outcomes in the COMPANION study.
- Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing ...
- Carvedilol produces sustained long-term benefits: follow-up at 12 years.
- Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.
- The FDA regulatory process for drug and genetic diagnostic test approvals.
- High quality catalog of proteotypic peptides from human heart.
- AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway.
- Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences.
- Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANIO...
- The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective.
- The pathophysiology of acute heart failure--it is a lot about fluid accumulation.
- Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST).
- Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers.
- Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
- Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure.
- Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial.
- Cardiac resynchronization therapy and adrenergic mechanisms.
- Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling.
- A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction.
- A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
- The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs.
- Serial gene expression profiling in the intact human heart.
- Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.
- Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
- Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
- Rationale and design of the enoximone clinical trials program.
- Cardiac resynchronization--a heart failure perspective.
- Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium.
- Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy.
- Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase.
- Mechanisms and models in heart failure: the biomechanical model and beyond.
- The COMET trial.
- Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy.
- Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopa...
- The emerging pharmacogenomics of the beta-adrenergic receptors.
- Simultaneous quantification of human cardiac alpha- and beta-myosin heavy chain proteins by MALDI-TOF mass spectrometry.
- Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers.
- Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
- Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2.
- Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate.
- Microarray measurements of gene expression before and after left ventricular assist device placement.
- Drug therapy and heart failure prevention.
- Association of serum digoxin concentration and outcomes in patients with heart failure.
- Selective activation of N-acyl-D-glucosamine 2-epimerase expression in failing human heart ventricular myocytes.
- Hypoplastic left heart syndrome myocytes are differentiated but possess a unique phenotype.
- Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before...
- Cardiotrophin-1 in heart failure.
- Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.
- Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium.
- Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.
- The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
- Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association.
- Sex-related differences in age-associated downregulation of human ventricular myocardial β1-adrenergic receptors.
Schools
UNIVERSITY OF ILLINOIS COLLEGE OF MEDICINE
Stanford University Program
Stanford Hospital and Clinics Program
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Elected Member
- Fellow (FACC)
Education
-
Stanford University -
University of Illinois College of Medicine
Hospital
-
University of Colorado Hospital
Helpful Reviews
Similar Doctors
|
Dr. Raphael Sung, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Gregory D. Ross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salman M. Azam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amber Khanna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan G. Aleong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bertron M. Groves, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amrut V. Ambardekar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David F. Katz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan M. Polizzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph L. Schuller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Shander, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Brian Stauffer, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John C. Messenger, MD
This Doctor is OpenDoctor Recommended.
|